Showing results (91-100 of 379) with videos related to

Sort By:
Pageof 38
Oncoimmunology|May 4, 2016
Vemurafenib and ipilimumab: A promising combination? Results of a case seriesJessica C Hassel, Sophia B Lee, Frank Meiss, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 2021
Male fertility during and after immune checkpoint inhibitor therapy: A cross-sectional pilot studyMartin Salzmann, Georgi Tosev, Melanie Heck, et al.
Cancer Immunology, Immunotherapy : CII|January 3, 2025
CMV IgG in the blood is not associated with hepatitis but correlates with poor outcomes in immunotherapy treated melanoma patientsSophia B Strobel, Devayani Machiraju, Melanie Wiecken, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 8, 2012
Escalating therapy of cutaneous side effects of EGFR inhibitors: experience of German reference centersBernhard Homey, Peter Arne Gerber, Andreas Wollenberg, et al.
Current Oncology (Toronto, Ont.)|April 27, 2026
Re-Exposure of a PD-1 Inhibitor After Previous Immune-Related Adverse EventsJana Burghaus-Zhang, Carsten Schulz, Egle Ramelyte, et al.
Der Pathologe|March 25, 2020
[Malignant melanoma]Georg Lodde, Lisa Zimmer, Elisabeth Livingstone, et al.
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete|November 28, 2019
[Malignant melanoma]Georg Lodde, Lisa Zimmer, Elisabeth Livingstone, et al.
Frontiers in Oncology|June 10, 2021
Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG StudyKatharina C Kähler, Ralf Gutzmer, Friedegrund Meier, et al.
Lancet (London, England)|July 14, 2023
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trialJürgen C Becker, Selma Ugurel, Ulrike Leiter, et al.
European Journal of Cancer (Oxford, England : 1990)|February 2, 2024
Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockadeEleftheria Chorti, Bernd Kowall, Jessica C Hassel, et al.
Pageof 38